SciSparc (NASDAQ:SPRC) Stock Price Down 2.8% – Should You Sell?

Shares of SciSparc Ltd. (NASDAQ:SPRC) fell 2.8% on Friday . The company traded as low as $2.07 and last traded at $2.1570. 432,494 shares traded hands during mid-day trading, a decline of 83% from the average session volume of 2,584,038 shares. The stock had previously closed at $2.22.

Analyst Ratings Changes

SPRC has been the subject of several recent research reports. Wall Street Zen upgraded shares of SciSparc to a “sell” rating in a research report on Saturday, September 13th. Weiss Ratings reissued a “sell (e+)” rating on shares of SciSparc in a research note on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, SciSparc has a consensus rating of “Sell”.

SciSparc Trading Down 2.8%

The company’s 50 day moving average price is $3.59 and its 200 day moving average price is $4.93.

About SciSparc

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution.